Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

FDA Grants Priority Review to Acalabrutinib in Treatment-Naive Mantle Cell Lymphoma

October 3rd 2024

The FDA granted priority review to acalabrutinib for previously untreated mantle cell lymphoma.

Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT

October 3rd 2024

A committee recommended a phase 1/2 study of ribaxamase for the prevention of acute graft-vs-host-disease proceed with enrollment for a third cohort.

HER2-Directed ADCs Spread Like Wildfire Across the Spectrum of Solid Malignancies

October 1st 2024

A panel of experts take stock of the current standing of HER2-directed ADCs in solid tumors, including breast, gynecologic, GI, lung, and GU cancers.

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC

October 1st 2024

The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

September 26th 2024

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

Toripalimab Plus Chemo Wins European Approval for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

September 25th 2024

The European Commission has approved toripalimab in indications for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.

KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly Diagnosed Myeloma Discontinues Enrollment

September 25th 2024

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

LODER Plus SOC Chemotherapy Elicits Responses, Boosts OS in KRAS+ Unresectable, Locally Advanced Pancreatic Cancer

September 24th 2024

LODER plus chemotherapy led to responses and improved overall survival in unresectable, locally advanced pancreatic cancer.

Frontline Enfortumab Vedotin Plus Pembrolizumab Receives Approval in Japan for Unresectable Urothelial Carcinoma

September 24th 2024

Enfortumab vedotin plus pembrolizumab has been approved in Japan for first-line radically unresectable urothelial carcinoma.

Japan’s MHLW Approves Fruquintinib in Pretreated mCRC After Chemotherapy

September 24th 2024

Japan’s Ministry of Health, Labour, and Welfare approved fruquintinib in metastatic colorectal cancer following progression with chemotherapy.

NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC

September 19th 2024

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC

September 19th 2024

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

FDA Grants Orphan Drug Designation to CF33-hNIS for Cholangiocarcinoma

September 18th 2024

The FDA has granted orphan drug designation to the novel oncolytic virotherapy CF33-hNIS for cholangiocarcinoma.

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine/Venetoclax in Treatment-Naive AML

September 18th 2024

ICT01 plus azacitidine and venetoclax has received fast track designation from the FDA in patients with untreated AML unfit for induction chemotherapy.

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

September 17th 2024

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

September 17th 2024

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Perioperative Nivolumab Shows EFS Benefit vs Placebo in Resectable NSCLC

September 15th 2024

Perioperative nivolumab extended event-free survival vs placebo in patients with resectable non–small cell lung cancer.

Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma

September 15th 2024

Early switch therapy to atezolizumab after run-in with vemurafenib plus cobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive melanoma.

Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC

September 14th 2024

The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.

Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC

September 14th 2024

Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.

NEXT PAGE
PREVIOUS PAGE